Protection of mice from Bordetella pertussis respiratory infection using microencapsulated pertussis fimbriae
- PMID: 7668037
- DOI: 10.1016/0264-410x(95)99876-j
Protection of mice from Bordetella pertussis respiratory infection using microencapsulated pertussis fimbriae
Abstract
Conditions have been established which allow the efficient entrapment of Bordetella pertussis fimbriae in poly(lactide-co-glycolide) microspheres. Fimbriae released from the matrix were found to have retained some degree of conformational structure, as determined by assessing the capacity of fimbrial protein to bind to antibodies mapping to either conformational or denatured structures on the fimbriae, either encapsulated in microspheres with a mean diameter of 24 microns and an estimated in vitro protein release rate of approximately 42 days, or conventionally adjuvanted with alhydrogel, elicited vigorous immune responses in mice. The encapsulated fimbriae appear to elicit marginally lower serum antibody levels than those induced by equivalent amounts of alhydrogel-adjuvanted fimbriae. Mice immunised with both preparations were, however, protected against intranasal infection with live B. pertussis as evidenced by the significant reduction in levels of bacterial colonisation observed in the lungs and tracheas of immunised animals when compared to the immunologically naive controls.
Similar articles
-
Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection.Infect Immun. 1996 Feb;64(2):489-94. doi: 10.1128/iai.64.2.489-494.1996. Infect Immun. 1996. PMID: 8550197 Free PMC article.
-
Poly(lactide-co-glycolide) microencapsulation of vaccine antigens.J Biotechnol. 1996 Jan 26;44(1-3):29-36. doi: 10.1016/0168-1656(95)00097-6. J Biotechnol. 1996. PMID: 8717383
-
Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.Vaccine. 2018 Mar 7;36(11):1345-1352. doi: 10.1016/j.vaccine.2018.02.017. Epub 2018 Feb 9. Vaccine. 2018. PMID: 29433898
-
How to make sense of pertussis immunogenicity data.Clin Infect Dis. 2001 Dec 15;33 Suppl 4:S288-91. doi: 10.1086/322564. Clin Infect Dis. 2001. PMID: 11709761 Review.
-
Bordetella pertussis fimbriae (Fim): relevance for vaccines.Expert Rev Vaccines. 2014 Oct;13(10):1205-14. doi: 10.1586/14760584.2014.930667. Epub 2014 Aug 8. Expert Rev Vaccines. 2014. PMID: 25102891 Review.
Cited by
-
Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1.Front Immunol. 2018 Feb 28;9:345. doi: 10.3389/fimmu.2018.00345. eCollection 2018. Front Immunol. 2018. PMID: 29541072 Free PMC article. Review.
-
Receptor-mediated targeting of spray-dried lipid particles coformulated with immunoglobulin and loaded with a prototype vaccine.Pharm Res. 2001 Jul;18(7):971-9. doi: 10.1023/a:1010988311640. Pharm Res. 2001. PMID: 11496957
-
Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells.Infect Immun. 1999 Mar;67(3):1050-5. doi: 10.1128/IAI.67.3.1050-1055.1999. Infect Immun. 1999. PMID: 10024542 Free PMC article.
-
Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.Infect Immun. 1996 Oct;64(10):4078-84. doi: 10.1128/iai.64.10.4078-4084.1996. Infect Immun. 1996. PMID: 8926072 Free PMC article.
-
Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection.Infect Immun. 1996 Feb;64(2):489-94. doi: 10.1128/iai.64.2.489-494.1996. Infect Immun. 1996. PMID: 8550197 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical